Targeted protein degradation field overview: clinical programs, target coverage, and deal flow across leading PROTAC and molecular glue companies. Kymera is the only company with multiple clinical-stage degrader programs in immunology.
Each cell shows the highest clinical phase for that company in that target. Filter by disease area to focus the view.
| IMMU | IMMU | IMMU | ONCO | ONCO | ONCO | ONCO | ONCO | ONCO | ONCO | ONCO | ONCO | NEUR | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | STAT6 | IRAK4 | IRF5 | ER/ESR1 | AR | CDK2 | BTK | EGFR | BRAF | GSPT1 | IKZF1/3 | IKZF2 | LRRK2 |
Kymera KYMR | — | — | — | — | — | — | — | — | — | ||||
Arvinas ARVN | — | — | — | — | — | — | — | — | — | — | |||
C4 Tx CCCC | — | — | — | — | — | — | — | — | — | — | |||
Nurix NRIX | — | — | — | — | — | — | — | — | — | — | — | — | |
Monte Rosa GLUE | — | — | — | — | — | — | — | — | — | — | — | ||
Plexium Private | — | — | — | — | — | — | — | — | — | — | — | — | |
Vividion Bayer (2021) | — | — | — | — | — | — | — | — | — | — | — | — |
No other TPD company has a clinical program targeting STAT6. KT-621 is an oral small molecule addressing a $15B+ market currently dominated by injectable biologics like Dupixent. Phase 2b data expected 2027.
IRF5 is a master regulator of innate immunity implicated in lupus, Sjögren's, and RA. No approved IRF5 therapy exists. KT-579 enters Phase 1 in 2026, opening an entirely new therapeutic node.
KT-485 is the 2nd-gen IRAK4 degrader, with superior potency and selectivity vs. predecessor KT-474. Sanofi partnership provides validation, global resources, and up to $2.1B in total potential value.
Only company with clinical-stage PROTAC programs in immunology (STAT6, IRAK4, IRF5). $1.6B cash (Dec 2025), Sanofi and Gilead partnerships. Dual FDA Fast Track for KT-621 (AD, asthma).
Pioneer TPD company. First PROTAC to reach Phase 3 (ARV-471). ~$650M Pfizer partnership. Led by founder Craig Crews.
Multiple partnerships: Roche (IKZF), Biogen, Merck KGaA. Clinical-stage in EGFR L858R, BRAF V600X, IKZF1/3.
Broadest E3 ligase toolkit (90+ validated ligases). Also exploring protein elevation. BMS and Gilead collaborations.
Focused exclusively on molecular glue degraders. QuEEN platform for novel glue discovery. Roche license deal.
Focused on molecular glue discovery for CNS and oncology targets. Series B funded.
Data from company investor presentations, press releases, ClinicalTrials.gov, and SEC filings. Phase classifications reflect highest reported clinical stage as of early 2026. This is not investment advice.